<?xml version="1.0" encoding="UTF-8"?>
<p id="Par22">Undoubtedly, further experimental and clinical data are required to clarify the role of RAAS modulation in COVID-19. The important issue that the outcome of a viral infection may be related to therapy provided for another underlying disease should be taken into consideration not only for COVID-19 but for other future viral or non-viral infections as well. In the meantime, it is important to caution that the strategy that we follow is the result of obligatory decision making in a period that solid data are lacking and new ones emerge daily regarding mechanisms, clinical characteristics, treatment options, and outcomes for COVID-19. Steadfast use of ACEi/ARB based on current guidelines should be strongly encouraged when there are no alternatives. Deviation from these practices until solid evidence becomes available should be avoided
 <italic>.</italic>
</p>
